X4 Pharmaceuticals (XFOR) Receivables - Net (2020 - 2026)

X4 Pharmaceuticals (XFOR) has reported Receivables - Net for 4 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 78.78% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (up 78.78% YoY), and the FY2025 full-year result was $573000.0, down 46.45% from the prior year.
• Receivables - Net climbed to $2.0 million in Q2 2026 per XFOR's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $2.0 million in Q2 2026 and bottomed at $509000.0 in Q1 2025.
• Historically, Receivables - Net has averaged $1.0 million across 3 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net sank 46.45% in 2025, then soared 118.66% in 2026.
• Over 3 years, Receivables - Net stood at $1.1 million in 2024, then tumbled by 46.45% to $573000.0 in 2025, then surged by 257.24% to $2.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $2.0 million, $1.1 million, and $573000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.